Slide 1: A New Paradigm in Oral Drug Delivery with the Precision Timed Release Platform
A New Paradigm in Oral Drug Delivery with the Precision Timed Release™ Platform Cingulate | Corporate Presentation October 2026
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than st
Slide 3: The Cingulate Opportunity
3 The Cingulate Opportunity Nasdaq: CING Near-Term Catalyst o CTx-1301 Commercial Launch planned 2H 2027 o 100 million prescriptions in $10Bn target market o Unprecedented Clinical Data Providing Clear Differentiation o Leadership Team with 90+ years of ADHD Experience Long-Term Catalysts = Value Cr
Slide 4: Cingulate Leadership Team
4 CINGULATE LEADERSHIP TEAM • Pharmaceutical Executive Leader: 30+ years in CEO, • Experienced Financial Leader: 30+ years in Board of Director, and diverse roles across biotech & accounting and financial management across a variety pharma. Doctor of Pharmacy. Cingulate Co-Founder. of industries. •
Slide 5: Today's Opportunity
Today’s Opportunity CTx-1301 in US ADHD Market Ø Over 100 Million ADHD Prescriptions Ø Significant Unmet Needs and Dissatisfaction with Current Treatments Ø Novartis, J&J, Takeda (Shire) Out of ADHD Space with LOE of Vyvanse, Adderall XR, Concerta, and Focalin XR CING-US-130-0426
Slide 6: ADHD Today
6 ADHD Today • The Scale of Need: 22 million Americans with ADHD experience impaired quality of life, reduced productivity, diagnosis issues (mis-, over-, missed, delayed), and remaining social stigma despite millions of prescriptions annually • The Real-World Gap: Today’s extended-release therapies
Slide 7: The Problem: Where Today's ADHD Therapies Fall Short
7 The Problem: Where Today’s ADHD Therapies Fall Short What Does Differentiation Look Like? ADHD BRANDS APPROVED ATTRIBUTES1 UNMET NEEDS1 Fast Onset of Real-World Action Entire Active- Minimize Onset (hr) Duration ≤ 30 min Day Efficacy* Crash/Rebound Avoid Booster1 92% Vyvanse® 2007 1½-2 8-9 hours û
Slide 8: Recent Launches Lack Meaningful Clinical Innovation
8 Recent Launches Lack Meaningful Clinical Innovation ADHD BRANDS ATTRIBUTES1 UNMET NEEDS Real-World Fast Acting Entire Active- Avoid Avoid Product Onset Duration (≤ 30 min) Day Efficacy* Crash/Rebound Booster Quillivant / Chew® XR 60 mins 8 hours û û û û Mydayis® 2 or 4 hrs 16+ hours û û û û Adzeny
Slide 9: Tremendous Market Opportunity Regardless of Scenario
9 Tremendous Market Opportunity Regardless of Scenario >100 Million ADHD Prescriptions ~$8 Bn ($30-625/Rx ; Avg $80/Rx) MARKET 5% ADHD Market @ $80 = $400M 1% ADHD Market @ $495 = $495M 60 Million Extended-Release Stimulant TRx (Not Including Boosters = 38M TRx) Assume 1/3 Dissatisfaction (Actual >6
Slide 10: Reason to Believe
Reason to Believe Commissioned Market Research • Awareness, Trial, & Usage (ATU) • Social Media Tracking Detailed review available under confidentiality CING-US-130-0426
Slide 11: The Strategic Case for CTx-1301
The Strategic Case for CTx-1301 Dissatisfaction Defines the ADHD Opportunity $ THE PROBLEM THE OPPORTUNITY THE PATHWAY Reliable, Entire Active – Day Efficacy Eliminate the Booster need A Clear Reimbursement Path ▪ Adults need a true, once-daily ▪ Most HCPs indicate 40-60% of their ▪ Access & afforda
Slide 12: Key Research Reinforces CTx-1301 Opportunity
Key Research Reinforces CTx-1301 Opportunity ATU & Social Media Tracking confirm a market primed for change Current options fall short on duration, boosters are routine, and access/ affordability remains the key adoption gate. Strategic Questions Insights from ATU Study (n=200 HCP’s) o Adults need L
Slide 13: Pricing & Contracting Strategy To Ensure Affordable Access and Maximum Profit
Pricing & Contracting Strategy To Ensure Affordable Access and Maximum Profit Vyvanse, Concerta, Focalin XR & Adderall XR: • Own the ADHD Market with zero promotion & no contracting • All have generic equivalents since LOE • Combined branded sales of $2 Bn today 1. Plans not receiving considerable r
Slide 14: The Solution
The Solution CING-US-130-0426
Slide 15: Precision Timed Release (PTR) Platform
The Solution Starts with Our Proprietary Technology to 15 Optimize Treatment Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets Immediate Release Third Erosion Release Barrier Layers Second Release Film Coat See the PTR™ Platform in Action @ Ci
Slide 16: One Product Designed to Overcome All Unmet Needs
16 One Product Designed to Overcome All Unmet Needs Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate Booster Doses 7am Noon 3pm “Built-In Booster” 1 2 3 Subject ID: 01-510 CTx-1301 6.25-mg Focalin XR 5-mg Fast Onset Extended Efficacy Cingulate.com © 2026 Cingulate Inc. CING-US-130-042
Slide 17: Unprecedented Entire Active Day ADHD Coverage
17 Unprecedented Entire Active Day ADHD Coverage 40 PERMP – Adult Laboratory Workplace CTx-1301 (N=11) Placebo (N=10) ** 111% 35 * p < 0.05 ** p = 0.10 - 0.05 65% ** p = 0.089 Overall 30 * 57% 49% 141% * Percent Improvement 25 213% 91% Over Placebo 52% Active-Day ** 88% Improvement 20 158% vs Placeb
Slide 18: PERMP Effect Size
18 Magnitude of Treatment Effect and Reliability of CTx-1301 Across Patients Effect Size= Magnitude of Response / Standard Deviation (Standard Deviation Impacts Effect Size & Reliability) A Meta-Analysis conducted by Faraone and Glatt (Clin Psych 71:6 3.00 June 2010)1 using 11 published studies with
Slide 19: CTx-1301 Demonstrated Significantly Lower Adverse Events
19 CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE’s related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5 mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Patients with at least
Slide 20: How Cingulate Achieves Success
How Cingulate Achieves Success Commercialization & Go-To-Market Strategy CING-US-130-0426
Slide 21: Cingulate Driven Commercialization Leveraging Best in Industry Partners
Cingulate Driven Commercialization Leveraging Best in Industry Partners Cingulate.com © 2026 Cingulate Inc. CING-US-130-0426
Slide 22: Cingulate's Go-To-Market Strategy
Cingulate’s Go-To-Market Strategy From Traditional To Innovation Rep-driven, transactional engagement Insight-led orchestration of Omnichannel & Sales Team Static campaigns and brand-centric messaging Dynamic, personalized journeys based on HCP and patient needs Fragmented national-local operations
Slide 23: Launch Ready with Best in Industry Commercialization
Launch Ready with Best in Industry Commercialization Essential Factors To Drive Demand 1. Reimbursement Cingulate Sales Professional Team: • Payer Research indicates Positive Acceptance for Reimbursement • 130 – 150 FTEs at Launch • Pricing & Contracting to Maximize GTN and ‘Lives Covered’ • 40-60 S
Slide 24: An Optimized Pharma Launch
An Optimized Pharma Launch — ROI Focused Capital Deployment Via Orchestration of Omnichannel & Sales Team A balanced, capital-efficient channel mix where scale is earned not given ATTRIBUTION SYNERGY Where the lift comes from Why the two strategies compound into the biggest TRx lift Illustrative exa
Slide 25: Exclusivity
Exclusivity CING-US-130-0426
Slide 26: CTx-1301 Patent Portfolio
26 CTx-1301 PATENT PORTFOLIO 2042 (15 Years from Launch): CTx-1301 Loss of Exclusivity • CTx-1301 Composition of Matter patents to be listed in FDA Orange Book o US Patent Application No. 18/560,039, NOA issued, product specific composition of matter patent protection to 2042 o US Patent No. 11,065,
Slide 27: The Future
The Future Vast Pipeline Opportunities via PTR™ Platform CING-US-130-0426
Slide 28: Identified Targets for PTR Platform Pipeline
28 Precision Timed Release™ Provides a New Paradigm for Oral Medications Identified Targets for PTRTM Platform Pipeline Significant Unmet Needs in Billion Dollar Markets In Development Near-Term Targets Identified Future Therapeutic Areas • ADHD (CTx-1301, 1302) • Insomnia • Migraine • Anxiety (CTx-
Slide 29: Thank You
Thank You CING-US-130-0426